Insufficient scRNA-seq data for expression of IGHV2-70 at single-cell level.
Insufficient scRNA-seq data for expression of IGHV2-70 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 69% | 160.06 | 398 / 578 | 74% | 107.59 | 853 / 1155 |
stomach | 55% | 147.56 | 199 / 359 | 47% | 48.10 | 134 / 286 |
spleen | 94% | 1228.45 | 226 / 241 | 0% | 0 | 0 / 0 |
intestine | 45% | 142.97 | 438 / 966 | 42% | 37.03 | 219 / 527 |
tonsil | 0% | 0 | 0 / 0 | 73% | 169.32 | 33 / 45 |
breast | 33% | 60.01 | 151 / 459 | 38% | 41.61 | 430 / 1118 |
bladder | 19% | 68.86 | 4 / 21 | 34% | 25.12 | 170 / 504 |
esophagus | 11% | 14.09 | 157 / 1445 | 40% | 44.82 | 73 / 183 |
uterus | 10% | 8.38 | 17 / 170 | 34% | 38.40 | 154 / 459 |
pancreas | 3% | 3.19 | 9 / 328 | 38% | 26.14 | 67 / 178 |
thymus | 18% | 72.41 | 117 / 653 | 22% | 22.51 | 132 / 605 |
peripheral blood | 40% | 184.44 | 369 / 929 | 0% | 0 | 0 / 0 |
kidney | 19% | 38.71 | 17 / 89 | 16% | 23.86 | 141 / 901 |
skin | 1% | 0.77 | 16 / 1809 | 33% | 53.56 | 157 / 472 |
ovary | 6% | 6.01 | 11 / 180 | 23% | 48.98 | 100 / 430 |
liver | 18% | 11.04 | 41 / 226 | 8% | 4.07 | 33 / 406 |
prostate | 14% | 13.66 | 35 / 245 | 9% | 3.29 | 44 / 502 |
lymph node | 0% | 0 | 0 / 0 | 21% | 5.91 | 6 / 29 |
adipose | 11% | 30.10 | 136 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 11% | 15.26 | 145 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 7% | 21.74 | 18 / 258 | 3% | 1.38 | 8 / 230 |
heart | 2% | 3.12 | 17 / 861 | 0% | 0 | 0 / 0 |
brain | 0% | 0.13 | 4 / 2642 | 2% | 0.76 | 11 / 705 |
eye | 0% | 0 | 0 / 0 | 1% | 0.15 | 1 / 80 |
muscle | 0% | 0.11 | 3 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006955 | Biological process | immune response |
GO_0016064 | Biological process | immunoglobulin mediated immune response |
GO_0019814 | Cellular component | immunoglobulin complex |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0003823 | Molecular function | antigen binding |
Gene name | IGHV2-70 |
Protein name | Immunoglobulin heavy variable 2-70 (Ig heavy chain V-II region COR) (Ig heavy chain V-II region DAW) (Ig heavy chain V-II region OU) (Ig heavy chain V-II region SESS) IGHV2-70 protein Immunoglobulin heavy variable 2-70 |
Synonyms | |
Description | FUNCTION: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition . Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens . The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen . . |
Accessions | ENST00000617374.2 A0A0J9YVU5 A0A0F7T0G6 A0A0F7T024 P01814 ENST00000632173.1 A0A0F7SZ86 |